InsiderTrades

Form 4 for MRNA Moderna

Accepted 2025-03-03 00:00:00 ET · period of report 2025-02-28 · accession 0001127602-25-007550 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-03-03 2025-02-28 MRNA Mock James M CFO M - OptEx — +329 15.0K +2% —
D 2025-03-03 2025-02-28 MRNA Mock James M CFO F - Tax $31.09 -160 14.9K -1% -$4,974
DM 2025-03-03 2025-03-01 MRNA Mock James M CFO A - Grant $0.00 +103.1K 63.5K New $0
D 2025-03-03 2025-02-28 MRNA Mock James M CFO M - OptEx $0.00 -329 2,630 -11% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-02-28 M A 329 — 15,034 D — — (F1) Restricted stock units convert into common stock on a one-for-one basis.
2 Common Common Stock 2025-02-28 F D 160 $31.09 14,874 D — —
3 Derivative Restricted Stock Units 2025-03-01 A A 39,606 $0.00 39,606 D — · — to — 39,606 Common Stock (F1) Restricted stock units convert into common stock on a one-for-one basis. (F5) 25% of the shares subject to this restricted stock unit award will vest on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
4 Derivative Restricted Stock Units 2025-02-28 M D 329 $0.00 2,630 D — · — to — 329 Common Stock (F1) Restricted stock units convert into common stock on a one-for-one basis. (F3) 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
5 Derivative Stock Option (Right to Buy) 2025-03-01 A A 63,478 $0.00 63,478 D $30.96 · 2026-03-01 to 2035-03-01 63,478 Common Stock (F4) 25% of this option will vest and become exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.